Kumar Anil, Kulkarni S K
University Institute of Pharmaceutical Science, Panjab University, Chandigarh 160 014, India.
Indian J Exp Biol. 2006 Jan;44(1):45-8.
Parkinson's disease (PD) is a neurodegenerative disease characterized by the selective loss of dopamine (DA) neurons of the substantia nigra pars compacta (SNc). The events, which trigger and/or mediate the loss of nigral DA neurons, however, remain unclear. Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism. Administration of haloperidol (1 mg/kg, ip) or reserpine (2 mg/kg, ip) significantly induced catalepsy in mice. BR-16A (50 and 100 mg/kg, po), a polyherbal formulation or ashwagandha (50 and 100 mg/kg, po), significantly reversed the haloperidol or reserpine-induced catalepsy. The results indicate that BR-16A or ashwagandha has protective effect against haloperidol or reserpine-induced catalepsy and provide hope that BR-16A could be used in preventing the drug-induced extrapyramidal side effects and may offer a new therapeutic approach to the treatment of Parkinson's disease.
帕金森病(PD)是一种神经退行性疾病,其特征是黑质致密部(SNc)的多巴胺(DA)神经元选择性丧失。然而,触发和/或介导黑质DA神经元丧失的事件仍不清楚。长期以来,抗精神病药物诱发的僵住症一直被用作筛选治疗帕金森病药物的动物模型。给予氟哌啶醇(1毫克/千克,腹腔注射)或利血平(2毫克/千克,腹腔注射)可显著诱导小鼠出现僵住症。多草药配方BR-16A(50和100毫克/千克,口服)或南非醉茄(50和100毫克/千克,口服)可显著逆转氟哌啶醇或利血平诱发的僵住症。结果表明,BR-16A或南非醉茄对氟哌啶醇或利血平诱发的僵住症具有保护作用,并为BR-16A可用于预防药物诱发的锥体外系副作用以及可能为帕金森病的治疗提供一种新的治疗方法带来了希望。